search
Back to results

The BIFSORB Pilot Study II (BIFSORB P-II)

Primary Purpose

Coronary Artery Disease

Status
Active
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Magmaris
Sponsored by
Aarhus University Hospital Skejby
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Coronary Artery Disease focused on measuring Percutaneous intervention (PCI), Optical coherence tomography (OCT), Bifurcation lesion, Bioresorbable stents (BRS)

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Stable angina pectoris
  • Stabilized non-ST elevation myocardial infarction
  • Silent angina pectoris
  • Age > 18 years
  • De novo coronary bifurcation lesion at LAD/diagonal, CX/obtuse marginal or RCA-PDA/posterolateral branch
  • All Medina classes except Medina x.x.1.
  • Diameter of side branch ≥ 2.5 mm
  • Side branch diameter stenosis less than 50%
  • Signed informed consent

Exclusion Criteria:

  • ST-elevation infarction within 48 hours
  • Expected survival < 1 year
  • Severe heart failure (NYHA≥III)
  • S-creatinine > 120 µmol/L or GFR < 0.45 mL/min per 1.73 m2
  • Allergy to contrast media, aspirin, clopidogrel, ticagrelor, ticlopidine or sirolimus
  • Unable to cover main vessel lesion with one stent
  • Severe tortuosity
  • Severe calcification

Sites / Locations

  • Aarhus University Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Magmaris

Arm Description

Implantation of sirolimus eluting bioresorbable magnesium stent

Outcomes

Primary Outcome Measures

Combined endpoint of: major procedural myocardial infarction, non-procedural myocardial infarction, target lesion failure and cardiac death
Combined endpoint of: major procedural myocardial infarction, non-procedural myocardial infarction, target lesion failure and cardiac death
Index of adverse vessel wall features by OCT
Index based on: side branch ostial area late loss, strut fracture, uncovered non-side branch apposed stent struts, uncovered stent struts in front of side branch, uncovered stent struts on acquired or persistent malapposed struts, persistent malapposition, max neointimal thickness/area stenosis, cumulated extra stent lumen gain

Secondary Outcome Measures

Optical coherence tomography endpoint: Acute malapposition
Optical coherence tomography endpoint: Acquired malapposition
Optical coherence tomography endpoint: Persistent malapposition
Optical coherence tomography endpoint: Coverage of jailing struts
Optical coherence tomography endpoint: Extra stent lumen (including evaginations)
Optical coherence tomography endpoint: Late stent recoil
Optical coherence tomography endpoint: Stent fracture
Optical coherence tomography endpoint: Single end attached protruding (floating) struts or neointimal tissue resembling struts
Optical coherence tomography endpoint: Ostial strut loss
Optical coherence tomography endpoint: Mean neointimal thickness
Optical coherence tomography endpoint: Stent strut coverage
Optical coherence tomography endpoint: Minimal luminal area in segmental analysis
Optical coherence tomography endpoint: Minimal stent area in segmental analysis
Optical coherence tomography endpoint: Minimum stent expansion area %
Optical coherence tomography endpoint: Segmental area stenosis
Optical coherence tomography endpoint: Healing above calcified plaque
Optical coherence tomography endpoint: Healing above lipid plaque
Optical coherence tomography endpoint: Acute thrombus on struts
Optical coherence tomography endpoint: Late thrombus on struts
Optical coherence tomography endpoint: Acute expansion
Measured in segments with: 1) calcified plaque, 2) lipid plaque, 3) area after predilatation < 30% of reference area, 4) stenosed segments (>50% area stenosis) with no dissections after predilatation
Optical coherence tomography endpoint: Late recoil
Measured in segments with: 1) calcified plaque, 2) lipid plaque, 3) area after predilatation < 30% of reference area, 4) stenosed segments (>50% area stenosis) with no dissections after predilatation
Angiographic endpoint: Ostial side branch area stenosis
Angiographic endpoint: Ostial side branch acute gain after main vessel stenting
Angiographic endpoint: Ostial side branch late loss
Angiographic endpoint: Ostial distal main vessel area stenosis
Angiographic endpoint: Ostial distal main vessel acute gain after main vessel stenting
Angiographic endpoint: Ostial distal main vessel late loss
Angiographic endpoint: Proximal main vessel area stenosis
Angiographic endpoint: Proximal main vessel acute gain after main vessel stenting
Angiographic endpoint: Proximal main vessel late loss
Angiographic endpoint: Minimal luminal area of all segments
Procedural endpoint: Procedure time
Procedural endpoint: Contrast use in mL
Procedural endpoint: Fluoroscopy time
Combined endpoint of: major procedural myocardial infarction, non-procedural myocardial infarction, target lesion failure and cardiac death
Combined endpoint of: major procedural myocardial infarction, non-procedural myocardial infarction, target lesion failure and cardiac death
Combined endpoint of: major procedural myocardial infarction, non-procedural myocardial infarction, target lesion failure and cardiac death
Combined endpoint of: major procedural myocardial infarction, non-procedural myocardial infarction, target lesion failure and cardiac death
Combined endpoint of: major procedural myocardial infarction, non-procedural myocardial infarction, target lesion failure and cardiac death
Combined endpoint of: major procedural myocardial infarction, non-procedural myocardial infarction, target lesion failure and cardiac death

Full Information

First Posted
November 22, 2016
Last Updated
January 5, 2021
Sponsor
Aarhus University Hospital Skejby
search

1. Study Identification

Unique Protocol Identification Number
NCT03027856
Brief Title
The BIFSORB Pilot Study II
Acronym
BIFSORB P-II
Official Title
A Sirolimus Eluting Bioresorbable Magnesium Stent for Treatment of Coronary Bifurcation Lesions - The BIFSORB Pilot Study II
Study Type
Interventional

2. Study Status

Record Verification Date
January 2021
Overall Recruitment Status
Active, not recruiting
Study Start Date
September 2016 (Actual)
Primary Completion Date
August 19, 2019 (Actual)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Aarhus University Hospital Skejby

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to investigate the feasibility and safety of the Magmaris BRS for treatment of coronary bifurcation lesions.
Detailed Description
Bioresorbable stents are promising in treatment of coronary artery disease. The concept of bifurcation treatment using BRS is particular appealing as struts covering the side branch ostium may resorb over time. The aim of this study is to investigate the feasibility and safety of the Magmaris BRS for treatment of coronary bifurcation lesions. Hypothesis: treatment of coronary bifurcation lesions using the Magmaris BRS is safe and feasible. Methods: The study is a proof-of-concept, prospective, single arm study with inclusion of 20 patients. Planned 1-and 12-month follow-up by optical coherence tomography (OCT) and follow-up for clinical endpoints until 5 years. Written informed consent is required before the procedure is performed. Eligible patients with a bifurcation lesion are treated by the provisional technique with mandatory jailing of the side branch and provisional opening of side branch ostium by the mini-kiss technique in case of severe pinching or TIMI-flow less than III. Proximal post-dilatation is mandatory. No dilatation beyond the expansion limits of the stent. At baseline, the target lesion is assessed by OCT before, during and after implantation of the Magmaris BRS. OCT assessment is performed again at 1- and 12-month follow-up, or before if the patient is readmitted with a possible target lesion failure. The operator is not blinded to the OCT images as pre-PCI images should be used for sizing and positioning of the stent, and procedural OCT images are used to optimize stent implantation before performing final OCT.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease
Keywords
Percutaneous intervention (PCI), Optical coherence tomography (OCT), Bifurcation lesion, Bioresorbable stents (BRS)

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Magmaris
Arm Type
Experimental
Arm Description
Implantation of sirolimus eluting bioresorbable magnesium stent
Intervention Type
Device
Intervention Name(s)
Magmaris
Intervention Description
Implantation of a sirolimus eluting bioresorbable magnesium stent
Primary Outcome Measure Information:
Title
Combined endpoint of: major procedural myocardial infarction, non-procedural myocardial infarction, target lesion failure and cardiac death
Description
Combined endpoint of: major procedural myocardial infarction, non-procedural myocardial infarction, target lesion failure and cardiac death
Time Frame
1 month
Title
Index of adverse vessel wall features by OCT
Description
Index based on: side branch ostial area late loss, strut fracture, uncovered non-side branch apposed stent struts, uncovered stent struts in front of side branch, uncovered stent struts on acquired or persistent malapposed struts, persistent malapposition, max neointimal thickness/area stenosis, cumulated extra stent lumen gain
Time Frame
1 month
Secondary Outcome Measure Information:
Title
Optical coherence tomography endpoint: Acute malapposition
Time Frame
Baseline
Title
Optical coherence tomography endpoint: Acquired malapposition
Time Frame
1 month
Title
Optical coherence tomography endpoint: Persistent malapposition
Time Frame
1 month
Title
Optical coherence tomography endpoint: Coverage of jailing struts
Time Frame
1 month
Title
Optical coherence tomography endpoint: Extra stent lumen (including evaginations)
Time Frame
Baseline and 1 month
Title
Optical coherence tomography endpoint: Late stent recoil
Time Frame
1 month
Title
Optical coherence tomography endpoint: Stent fracture
Time Frame
Baseline and 1 month
Title
Optical coherence tomography endpoint: Single end attached protruding (floating) struts or neointimal tissue resembling struts
Time Frame
Baseline and 1 month
Title
Optical coherence tomography endpoint: Ostial strut loss
Time Frame
Baseline and 1 month
Title
Optical coherence tomography endpoint: Mean neointimal thickness
Time Frame
1 month
Title
Optical coherence tomography endpoint: Stent strut coverage
Time Frame
1 month
Title
Optical coherence tomography endpoint: Minimal luminal area in segmental analysis
Time Frame
Baseline and 1 month
Title
Optical coherence tomography endpoint: Minimal stent area in segmental analysis
Time Frame
Baseline and 1 month
Title
Optical coherence tomography endpoint: Minimum stent expansion area %
Time Frame
Baseline and 1 month
Title
Optical coherence tomography endpoint: Segmental area stenosis
Time Frame
Baseline and 1 month
Title
Optical coherence tomography endpoint: Healing above calcified plaque
Time Frame
1 month
Title
Optical coherence tomography endpoint: Healing above lipid plaque
Time Frame
1 month
Title
Optical coherence tomography endpoint: Acute thrombus on struts
Time Frame
Baseline
Title
Optical coherence tomography endpoint: Late thrombus on struts
Time Frame
1 month
Title
Optical coherence tomography endpoint: Acute expansion
Description
Measured in segments with: 1) calcified plaque, 2) lipid plaque, 3) area after predilatation < 30% of reference area, 4) stenosed segments (>50% area stenosis) with no dissections after predilatation
Time Frame
Baseline
Title
Optical coherence tomography endpoint: Late recoil
Description
Measured in segments with: 1) calcified plaque, 2) lipid plaque, 3) area after predilatation < 30% of reference area, 4) stenosed segments (>50% area stenosis) with no dissections after predilatation
Time Frame
1 month
Title
Angiographic endpoint: Ostial side branch area stenosis
Time Frame
Baseline and 1 month
Title
Angiographic endpoint: Ostial side branch acute gain after main vessel stenting
Time Frame
Baseline
Title
Angiographic endpoint: Ostial side branch late loss
Time Frame
1 month
Title
Angiographic endpoint: Ostial distal main vessel area stenosis
Time Frame
Baseline and 1 month
Title
Angiographic endpoint: Ostial distal main vessel acute gain after main vessel stenting
Time Frame
Baseline
Title
Angiographic endpoint: Ostial distal main vessel late loss
Time Frame
1 month
Title
Angiographic endpoint: Proximal main vessel area stenosis
Time Frame
Baseline and 1 month
Title
Angiographic endpoint: Proximal main vessel acute gain after main vessel stenting
Time Frame
Baseline
Title
Angiographic endpoint: Proximal main vessel late loss
Time Frame
1 month
Title
Angiographic endpoint: Minimal luminal area of all segments
Time Frame
Baseline and 1 month
Title
Procedural endpoint: Procedure time
Time Frame
Intraoperative
Title
Procedural endpoint: Contrast use in mL
Time Frame
Intraoperative
Title
Procedural endpoint: Fluoroscopy time
Time Frame
Intraoperative
Title
Combined endpoint of: major procedural myocardial infarction, non-procedural myocardial infarction, target lesion failure and cardiac death
Description
Combined endpoint of: major procedural myocardial infarction, non-procedural myocardial infarction, target lesion failure and cardiac death
Time Frame
6 months
Title
Combined endpoint of: major procedural myocardial infarction, non-procedural myocardial infarction, target lesion failure and cardiac death
Description
Combined endpoint of: major procedural myocardial infarction, non-procedural myocardial infarction, target lesion failure and cardiac death
Time Frame
24 months
Title
Combined endpoint of: major procedural myocardial infarction, non-procedural myocardial infarction, target lesion failure and cardiac death
Description
Combined endpoint of: major procedural myocardial infarction, non-procedural myocardial infarction, target lesion failure and cardiac death
Time Frame
60 months
Other Pre-specified Outcome Measures:
Title
Clinical endpoint: myocardial infarction
Time Frame
5 years
Title
Clinical endpoint: target lesion failure
Time Frame
5 years
Title
Clinical endpoint: target lesion revascularization
Time Frame
5 years
Title
Clinical endpoint: stent thrombosis
Time Frame
5 years
Title
Clinical endpoint: cardiac death
Time Frame
5 years
Title
Clinical endpoint: non-cardiac death
Time Frame
5 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Stable angina pectoris Stabilized non-ST elevation myocardial infarction Silent angina pectoris Age > 18 years De novo coronary bifurcation lesion at LAD/diagonal, CX/obtuse marginal or RCA-PDA/posterolateral branch All Medina classes except Medina x.x.1. Diameter of side branch ≥ 2.5 mm Side branch diameter stenosis less than 50% Signed informed consent Exclusion Criteria: ST-elevation infarction within 48 hours Expected survival < 1 year Severe heart failure (NYHA≥III) S-creatinine > 120 µmol/L or GFR < 0.45 mL/min per 1.73 m2 Allergy to contrast media, aspirin, clopidogrel, ticagrelor, ticlopidine or sirolimus Unable to cover main vessel lesion with one stent Severe tortuosity Severe calcification
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Evald H Christiansen, MD, PhD
Organizational Affiliation
Aarhus University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Aarhus University Hospital
City
Aarhus N
ZIP/Postal Code
8000
Country
Denmark

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

The BIFSORB Pilot Study II

We'll reach out to this number within 24 hrs